ARCH Venture Fund XI, L.P. - Jul 30, 2021 Form 4 Insider Report for DA32 Life Science Tech Acquisition Corp. (DALS)

Role
10%+ Owner
Signature
/s/ Henrikki Harsu, Attorney-in-Fact for ARCH Venture Fund XI, L.P.
Stock symbol
DALS
Transactions as of
Jul 30, 2021
Transactions value $
$22,500,000
Form type
4
Date filed
8/3/2021, 09:06 PM
Previous filing
Jul 27, 2021
Next filing
Aug 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DALS Class A Common Stock Purchase $16M +1.6M $10.00 1.6M Jul 30, 2021 Direct F1, F2
transaction DALS Class A Common Stock Other $6.5M +650K +40.63% $10.00 2.25M Jul 30, 2021 Through A32 ponsor LC F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 ARCH Venture Fund XI, L.P. purchased 1,600,000 shares of the Issuer's Class A common stock for $10.00 per share in the Issuer's initial public offering.
F2 This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class A common stock and Class B Common Stock and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.
F3 DA32 Sponsor LLC ("Sponsor") purchased 650,000 shares of Class A common stock directly from the Issuer in a private placement for $10.00 per share, concurrently with the Issuer's initial public offering.
F4 As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.

Remarks:

See Exhibit 99.1 - Joint Filer Information, which is incorporated herein by reference and describes in further detail the relationships of the Reporting Persons to the Issuer. Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24.1, 24.2, 24.3, 24.4, 24.5 and 24.6 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, Kristina Burow, Robert Nelsen and Steven Gillis.